Drug intelligence / Profile preview

bertilimumab

Development stage: Phase 2
Lead developer: Immune Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Ophthalmic, Intranasal, Intravitreal

Overview

Bertilimumab is a fully human recombinant IgG4 monoclonal antibody that binds to eotaxin-1 (CCL11), an important regulator of eosinophil function. It is being developed for the treatment of allergic and inflammatory disorders such as bullous pemphigoid, allergic conjunctivitis, allergic rhinitis, Crohn’s disease, and ulcerative colitis. The drug was discovered by Cambridge Antibody Technology using phage display technology and has been further developed by companies including MedImmune (now part of AstraZeneca), iCo Therapeutics Inc., and Immune Pharmaceuticals Inc.

Other names: Anti-eotaxin human monoclonal antibodyIMMUNOGLOBULIN G4, ANTI-(HUMAN EOTAXIN 1) (HUMAN MONOCLONAL CAT-213 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CAT-213 .KAPPA.-CHAIN, DIMER

Targets

CCL11 (C-C motif chemokine ligand 11)

Beyond the preview

Go deeper on bertilimumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bertilimumab.

Explore the full profile